{
    "nct_id": "NCT04115293",
    "official_title": "A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis",
    "inclusion_criteria": "* Diagnosis of gMG [Myasthenia Gravis Foundation of America (MGFA) Class II-IV] at Screening\n* Positive serology for acetylcholine receptor (AChR) autoantibodies\n* MG-ADL Score of ≥ 6 at Screening and Baseline\n* QMG score ≥ 12 at Screening and Baseline\n* No change in corticosteroid dose for at least 30 days prior to Baseline or anticipated to occur during the 12-week Treatment Period\n* No change in immunosuppressive therapy, including dose, for at least 30 days prior to Baseline or anticipated to occur during the 12-week Treatment Period\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 74 Years",
    "exclusion_criteria": "* Thymectomy within 12 months prior to Baseline or scheduled to occur during the 12 week Treatment Period\n* History of meningococcal disease\n* Current or recent systemic infection within 2 weeks prior to Baseline or injection requiring intravenous (IV) antibiotics within 4 weeks prior to Baseline",
    "miscellaneous_criteria": ""
}